Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After An 84% One Year Share Price Jump

Simply Wall St.04-02

If you are wondering whether Syndax Pharmaceuticals' current share price reflects its true worth, this article walks through the key valuation checks that can help you frame that question clearly. The...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624579802?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-02 14:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624579802","market":"sg","top_or_hot":-1,"title":"Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After An 84% One Year Share Price Jump","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Syndax Pharmaceuticals' current share price reflects its true worth, this article walks through the key valuation checks that can help you frame that question clearly. The...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/is-it-time-to-reassess-syndax-pharmaceuticals-sndx-after-an\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After An 84% One Year Share Price Jump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time To Reassess Syndax Pharmaceuticals (SNDX) After An 84% One Year Share Price Jump\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-02 14:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/is-it-time-to-reassess-syndax-pharmaceuticals-sndx-after-an><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Syndax Pharmaceuticals' current share price reflects its true worth, this article walks through the key valuation checks that can help you frame that question clearly. The...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/is-it-time-to-reassess-syndax-pharmaceuticals-sndx-after-an\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/is-it-time-to-reassess-syndax-pharmaceuticals-sndx-after-an","article_id":"2624579802","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/is-it-time-to-reassess-syndax-pharmaceuticals-sndx-after-an","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624579802","pubTimestamp":1775111446,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Syndax Pharmaceuticals' current share price reflects its true worth, this article walks through the key valuation checks that can help you frame that question clearly.\nThe stock recently closed at US$23.88, after a 7.9% gain over the past month, a 12.1% return year to date, and 84.1% over the last year. These moves may have changed how the market views both its potential and its risks.\nRecent coverage has focused on Syndax Pharmaceuticals in the context of its...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SNDX":"Syndax Pharmaceuticals, Inc. ","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"Syndax Pharmaceuticals(SNDX)股价一年上涨84%后，是时候重新评估它了吗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"SNDX":1.5},"content_text":"If you are wondering whether Syndax Pharmaceuticals' current share price reflects its true worth, this article walks through the key valuation checks that can help you frame that question clearly. The stock recently closed at US$23.88, after a 7.9% gain over the past month, a 12.1% return year to date, and 84.1% over the last year. These moves may have changed how the market views both its potential and its risks. Recent coverage has focused on Syndax Pharmaceuticals in the context of its sector peers and how investor expectations have evolved over time. This broader attention helps explain why the share price performance over 1 year and 3 years, at 84.1% and 18.8% respectively, is an important backdrop for any valuation discussion. Syndax Pharmaceuticals currently records a value score of 3/6, based on how it screens across six separate valuation checks. The next sections will compare different valuation approaches and then finish with a more complete way to think about whether the stock looks attractively priced.  Syndax Pharmaceuticals delivered 84.1% returns over the last year. See how this stacks up to the rest of the Biotechs industry. AdvertisementApproach 1: Syndax Pharmaceuticals Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and then discounting them back to today using a required rate of return. For Syndax Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in US$. The latest twelve month free cash flow is a loss of $323.4 million. Analysts have specific free cash flow estimates through 2030, such as $76 million in 2027 and $326.9 million in 2030, with further projections after that extrapolated rather than directly forecast by analysts. When all projected and extrapolated cash flows are discounted back, the DCF model indicates an intrinsic value of about $84.41 per share. Compared with the recent share price of $23.88, this output suggests the stock screens as around 71.7% undervalued on this method alone. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Syndax Pharmaceuticals is undervalued by 71.7%. Track this in your watchlist or portfolio, or discover 63 more high quality undervalued stocks. SNDX Discounted Cash Flow as at Apr 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Syndax Pharmaceuticals. Approach 2: Syndax Pharmaceuticals Price vs Sales For companies where earnings are not yet positive, the preferred metric is often the Price to Sales, or P/S, ratio because it compares what you pay for each dollar of revenue instead of each dollar of profit. This is useful when profits are still being built but revenue traction is visible. What counts as a reasonable P/S multiple typically reflects how fast investors expect revenue to grow and how much risk they see in the business model. Higher expected growth or lower perceived risk can support a higher P/S, while slower expected growth or higher uncertainty tend to support a lower one. Syndax Pharmaceuticals currently trades on a P/S of 12.22x. That sits above the Biotechs industry average of 10.95x and below the peer group average of 15.48x. Simply Wall St also calculates a “Fair Ratio” of 1.76x for Syndax Pharmaceuticals, a proprietary estimate of what the P/S might be given factors such as earnings growth profile, industry, profit margins, market cap and specific risks. The Fair Ratio can be more informative than a simple peer or industry comparison because it adjusts for this broader set of company specific drivers rather than assuming one size fits all. Comparing the Fair Ratio of 1.76x with the current 12.22x suggests the shares screen as expensive on this measure. Result: OVERVALUED NasdaqGS:SNDX P/S Ratio as at Apr 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies. Upgrade Your Decision Making: Choose your Syndax Pharmaceuticals Narrative Earlier it was mentioned that there is an even better way to understand valuation. Narratives step in as a simple way for you to attach a clear story about Syndax Pharmaceuticals to actual numbers such as your assumed fair value and expectations for future revenue, earnings and margins. You can then link that story to a forecast on Simply Wall St’s Community page where Narratives are available to millions of investors. This helps you compare fair value with the current share price to judge whether the stock looks cheap or expensive, and automatically refreshes your view when new information such as earnings or MAXPIRe data arrives. This is why one investor might build a cautious Syndax Narrative around a fair value near US$28 while another builds a more upbeat story around a fair value closer to US$56, each reflecting different beliefs about how Revuforj, Niktimvo and IPF opportunities could play out. Do you think there's more to the story for Syndax Pharmaceuticals? Head over to our Community to see what others are saying! NasdaqGS:SNDX 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624579802","isCrawlerRequest":true}